Related Experiment Video

Updated: Apr 7, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.6K

Role of angiotensin II type I (AT1 A1166C) receptor polymorphism in susceptibility of left ventricular dysfunction

Avshesh Mishra1, Anshika Srivastava1, Surendra Kumar1

  • 1Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow 226014, UP, India.

Indian Heart Journal
|July 4, 2015
PubMed

Insights

The AT1 A1166C gene variant is linked to a higher risk of left ventricular dysfunction (LVD) in patients with coronary artery disease (CAD). This genetic susceptibility may contribute to the development of heart failure.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetic Epidemiology

Background:

  • Left ventricular dysfunction (LVD) and congestive heart failure (CHF) are common endpoints of various cardiac conditions.
  • Impaired left ventricular function often follows ischemic events, activating the renin-angiotensin-system (RAS).
  • The Angiotensin II type I receptor (AT1) gene is a candidate for cardiovascular disease due to its role in RAS-mediated actions.

Purpose of the Study:

  • To investigate the association between a single nucleotide polymorphism (SNP) in the AT1 gene and LVD in patients with coronary artery disease (CAD).

Main Methods:

  • Recruited 950 subjects: 720 with angiography-confirmed CAD and 230 healthy controls.
  • Categorized 229 CAD patients with reduced left ventricle ejection fraction (LVEF ≤ 45%) as having LVD.
  • Determined AT1 (A1166C, rs5186) polymorphism using Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR).

Main Results:

  • Significantly higher frequencies of AT1 1166AC and CC genotypes were observed in LVD patients compared to non-LVD patients (p=0.003, OR=1.81; p<0.001, OR=4.33).
  • The AT1 A1166C polymorphism was significantly associated with left ventricular end-diastole, end-systole dimensions, and mean LVEF (p=0.031, p=0.038, p=0.035).
  • No significant association was found between AT1 A1166C polymorphism and CAD in comparisons with healthy controls at genotypic or allelic levels.

Conclusions:

  • The AT1 A1166C polymorphism may contribute to genetic susceptibility for developing left ventricular dysfunction.
  • This finding highlights a potential genetic marker for LVD risk in CAD patients.
Abstract

Keywords:
AT1 A1166C polymorphismCoronary artery diseaseLVDLVEF

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.9K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.8K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69